Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Microbiotica Limited has 1 pending office action within the Biotechnology & Pharmaceuticals sector. This activity is distributed among 1 distinct examiner and 1 distinct art unit. The portfolio's current state reflects a highly specialized focus, with all active prosecution occurring within a single technical silo. This arrangement simplifies the management of deadlines but increases the impact of any single procedural or substantive rejection from the USPTO.
ARMATO JR, DENNIS IGNATIUS is the busiest examiner for the company, managing 1 busiest examiner pending office action. This individual handles the 1 pending office action currently active for the entity. In the Biotechnology & Pharmaceuticals field, where examiner discretion can be significant, having only one point of contact requires a highly focused advocacy strategy. The legal team must align their arguments specifically with the prior art interpretations favored by ARMATO JR, DENNIS IGNATIUS.
The involvement of 1 distinct art unit suggests that the company's current intellectual property interests are confined to a specific niche. With 1 pending office action total, there is no opportunity to leverage different examiner perspectives across the portfolio. Success depends on a successful resolution with the current examiner to move the portfolio toward allowance. The 1 distinct examiner and 1 distinct art unit define the current boundaries of the company's patent strategy.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARMATO JR, DENNIS IGNATIUS | 1 | 42.9% | +80.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17834584 | Bacterial Biomarker | ARMATO JR, DENNIS IGNATIUS | — |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17834584 | Bacterial Biomarker | ARMATO JR, DENNIS IGNATIUS | 1651 | §102 | Final Rejection | — | Pending | Jun 07, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial